Research: HPV vaccine is safe RIVM research shows no causal link between the vaccine against cervical cancer (HPV) and long-term fatigue symptoms in girls.
Teen vaccination against meningococcal disease starts From mid-September, young people born between 1 May and 31 December 2004 will receive an invitation for a vaccination against meningococcal disease.
Vaccination rate again drops slightly, HPV vaccination rate drops considerably The vaccination rate for vaccines included in the National Immunisation Programme has dropped slightly by about 1 percent.
Meningococcal immunisation recommendations re-examined Meningococcal disease is a very serious infectious disease that can cause meningitis or blood poisoning. Children are immunised against meningococcal serogroup C at 14 months.
EFSA agrees with RIVM that potential effect of BPA on the immune system requires further attention RIVM expressed concerns on the effects of bisphenol a (BPA) on the immune system in a report issued in March 2016.
RIVM recommends more stringent EU standards BPA More stringent European standards for safe exposure of workers and consumers to bisphenol A (BPA) were proposed in 2014 and 2015.
CAESAR annual report 2014 The World Health Organization (WHO) published its first CAESAR annual report 2014.
Improving consumer exposure assessment to chemical substances By combining the available international knowledge, the method to assess the extent to which consumers are exposed to chemical substances via everyday products such as paint, cleaning agents and co
Half of the Dutch participate in sport weekly In 2014, 53% of people between the ages of 12 and 80 in the Netherlands participate in some type of sport weekly.
Risks of chemical substances to human health and the environment RIVM is developing methods to identify new and emerging risks of chemical substances to workers, consumers and the environment.